Arterial Remodeling With Hypertension

As Seen On...

We know that hypertension is associated with an increased risk of cardiovascular disease. We also know that hypertension is caused by a number of different mechanisms that result in elevated blood pressure. The blood vessel responds appropriately in an attempt to protect the fragile capillaries and prevent them from blowing out due to this increased pressure.

When arteries are exposed to increased pressures chronically, as in hypertension, they undergo changes. These changes can either be inward eutrophic remodeling or hypertrophic remodeling.1

Inward eutrophic remodeling the artery lumen, as well as the outer wall diameter are decreased. The media/lumen ratio is increased and the media cross-section remains the same.

Hypertrophic remodeling is where the media gets thicker and begins to move in to the lumen. This results in an increase in the media cross-sectional area and the media/lumen ratio.

Arterial remodeling occurs through inflammation, fibrosis, growth, and apoptosis which occur due to the hypertension.

Inflammation triggers fibrosis in hypertension and cardiovascular disease.

Fibrosis occurs through an increase in collagen, fibronectin and other extracellular matrix components in the arterial wall. Fibrosis is an important component of the extracellular matrix remodeling that occurs during hypertension.

Apoptosis, programmed cell death, helps to counter cell proliferation and helps adjust developmental growth. Apoptosis can be both increased and decreased in hypertension based on different tissues (including blood vessels).

These mechanisms result in remodeling of arteries and arterioles. These mechanisms are initially adaptive and protective to prevent blow out as previously mentioned. However, when these processes continue they become maladaptive and contribute to many of the negative effects associated with hypertension.

 

Cilazapril, an ACE-Inhibitor (ACEi), can reverse the impairment of ACh-induced relaxation in spontaneously hypertensive rats.2

Simvastatin combined with losartan imrpoves endothelial function and reduces inflammatory markers to a greater extent than monotherapy with either drug in hypercholesterolemic, hypertensive patients.3

These studies support the hypothesis that AT1 receptor blockade has beneficial effects on superoxide production and nitric oxide bioavailability above that of other classes of antihypertensive agents. Reduced expression of components of the NAD(P)H oxidase may contribute to these effects.4

CCBs, ACEi, and ARBs improve arterial compliance but BBs didn’t.5

Nifedipine treatment diminished the number of severe clinical outcomes in elderly hypertensives significantly.6

The change in small artery morphology caused by perindopril was not accompanied by any change in media cross-sectional area, suggesting that the change was due to “remodeling.”7 .

Although it is recognized that the cause of hypertension can be various, once blood pressure has become established structural changes emerge in the systemic vasculature. In medium- and large-sized vessels, as in the left ventricle, there is clear histological evidence of hypertrophy of the medial smooth muscle layers but, downstream in small arteries, which modulate vascular resistance, other changes occur. In essential hypertension, the smooth muscle cells of small vessels are restructured around a smaller lumen, but there is no evidence of hypertrophy or hyperplasia of the vascular wall. In secondary forms of hypertension, which tend to be representative of severer forms of the disease, hypertrophic remodelling is observed. Similarly, in non-insulin-dependent diabetes mellitus, irrespective of whether blood pressure accompanies this disorder or not, hypertrophy is also seen. The presence of architectural alterations in the vascular wall of small arteries may have a strong prognostic significance in patients, and this may be over and above all other known cardiovascular risk factors. Although it is yet to be established whether regression of such changes should be a goal of effective antihypertensive therapy, there is a body of evidence emerging indicating that different classes of antihypertensive drug have a varied effect on reversing vascular structure both in humans and animal models of genetic and experimental hypertension. However, at present, there are no data available concerning the prognostic impact of regressing vascular structural alterations in hypertension, and this must be an urgent research priority.8 .

Thus, hypertensive patients with blood pressure controlled with the combination per/ind had normalized capillary density and endothelial function, whereas other antihypertensive treatments, excluding ACE inhibitors or diuretics, had less effect despite similar blood pressure control.9 .

References

  1. Schiffrin E, Intengan H. Vascular Remodeling in Hypertension, Roles of Apoptosis, Inflammation, and Fibrosis. Hypertension. 2001;38:581–587.
  2. Young RH, Ding YA, Lee YM, Yen MH. Cilazapril reverses endothelium-dependent vasodilator response to acetylcholine in mesenteric artery from spontaneously hypertensive rats. Am J Hypertens. 1995 Sep;8(9):928-33.
  3. Kon Koh K, Michael J. Quon M, Hwan Han S, Chung W, Yeal Ahn J, Seo Y, Ho Kang M, Hoon Ahn T, Suck Choi I, Kyun Shin E. Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients. Circulation. 2004;110:3687–3692.
  4. Brosnan MJ1, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens. 2002 Feb;20(2):281-6.
  5. Resnick L, Lester M. Differential effects of antihypertensive drug therapy on arterial compliance. Am J of Hypertension. 2002 Dec;15(12):1096-1100.
  6. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Pagé V, Ghadirian P, LeLorier J, Hamet P. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996 Oct;14(10):1237-45.
  7. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995 Apr;25(4 Pt 1):474-81.
  8. Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens. 2009 Jun;27(6):1107-14.
  9. Debbabi H, Bonnin P, Levy BI. Effects of blood pressure control with perindopril/indapamide on the microcirculation in hypertensive patients. Am J Hypertens. 2010 Oct;23(10):1136-43.